Rigel Reports Third Quarter 2026 Financial Results

Rigel reported Q3 2026 revenue of $80.9 million, up 16% year over year, and net income of $13.2 million versus $27.9 million a year earlier. Product sales rose 13% to $72.3 million; newly launched VEPPANU contributed $6.6 million, while costs and expenses increased to $63.8 million from $41.0 million. Rigel narrowed 2026 revenue guidance to approximately $290–$295 million, excluding VEPPANU product sales, and continues to expect full-year profitability. Cash, cash equivalents and short-term investments were $99.3 million at September 30, 2026, down from $155.0 million at December 31, 2025.

Analysis

RIGL’s launch data create a potentially underappreciated guidance asymmetry: management’s 2026 revenue outlook explicitly excludes VEPPANU, so launch sales may sit above the stated range. Do not treat that as guaranteed upside until the call clarifies net economics, supply/partner arrangements, and whether any launch-related costs or accounting offsets are material. The key test is whether early prescriptions convert to repeat use and sustained quarterly sales—not the initial shipment count. In ESR1-mutated breast cancer, adoption will depend on reimbursement and physician sequencing against existing endocrine options, including elacestrant; launch execution can disappoint even with regulatory differentiation.

The more cautious read-through is operating leverage: higher R&D and commercial spending compressed quarterly operating income despite product growth. TAVALISSE and REZLIDHIA provide a growing base, but GAVRETO’s decline is a drag, while collaboration revenue is timing-sensitive. The prior-year comparison is also distorted by a one-time Lilly-related collaboration item; headline year-to-date revenue decline is not a clean measure of underlying product demand. Cash has fallen materially since year-end, so verify cash-flow drivers and runway rather than relying solely on the positive-net-income claim.

Near-term catalysts are today’s call and December ASH data. VEPPANU launch traction could re-rate the growth profile over 1–3 months; R289 remains a high-variance, longer-dated option, not yet a basis for assigning meaningful value. For GRFS and GUD, Rigel’s reported collaboration receipts and international TAVALISSE activity are unlikely to establish material earnings impact without partner-level disclosure. Contrarian risk: investors may overvalue launch enthusiasm while underweighting rising expenses and the quality/timing of collaboration revenue.

Key Decisions for Investors

• Do not chase RIGL ahead of today’s call. Consider a small, event-driven long only if management confirms VEPPANU repeat-use, reimbursement progress, and a credible path for launch sales to add to—not merely substitute for—2026 revenue; reassess after the call rather than assigning a price target without valuation and market data.
• Use the call to verify VEPPANU net economics and launch spending, the drivers of the cash decline, and quarterly cash-flow/runway expectations. Treat the stated revenue outlook as excluding VEPPANU, but do not model incremental earnings until these details are clear.
• Track the next quarterly report for VEPPANU sequential sales and refills, ex-VEPPANU product trends, and expense growth. Thesis weakens if launch sales fail to build, core product demand deteriorates, or operating costs continue rising faster than product revenue; ASH R289 data are a December catalyst, with dose selection expected by year-end.
• No actionable GRFS, GUD, or LLY trade is supported by the disclosed partner-level information; verify whether Rigel-related royalties, supply revenue, or international launches are material to those companies before trading them.